ArticleThe oncologist2015
Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies.
Article in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors associated with breast cancer screening participation among women in mainland China: a systematic review.BMJ open · 2019Pooled it
- Breast cancer in previously thyroidectomized patients: which thyroid disorders are a risk factor?Future science OA · 2021Trial
- Global patterns, temporal trends and socioeconomic inequalities in the burden of breast cancer: a population-based study across 185 countries.Cancer biology & medicine · 2026Article
- Breast Cancer Screening Programs in China: Implementation, Challenges, and Future Perspectives.Korean journal of radiology · 2026Review
- Article
- Estimating the Proportion of Overdiagnosis among Prostate, Breast, and Thyroid Cancers in China: Findings from the Global Burden of Disease 2019.Current oncology (Toronto, Ont.) · 2024Article
- Alteration of the immune microenvironment in the axillary metastatic lymph nodes of luminal A breast cancer patients.World journal of surgical oncology · 2024Article
- Article
- Trends in the Disease Burden and Risk Factors of Women's Cancers in China From 1990 to 2019.International journal of public health · 2024Article
- Psychometric evaluation of the Chinese version of the breast cancer perception scale for community women: a translation and validation study.Breast cancer (Tokyo, Japan) · 2024Article
- Ultrasound for Breast Cancer Screening in Resource-Limited Settings: Current Practice and Future Directions.Cancers · 2023Review
- Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003-2017).Breast cancer research and treatment · 2022Article
- Breast Cancer Mortality Trends and Predictions to 2030 and Its Attributable Risk Factors in East and South Asian Countries.Frontiers in nutrition · 2022Article
- Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018.Breast cancer research and treatment · 2021Article
- Hydroxyl safflower yellow B combined with doxorubicin inhibits the proliferation of human breast cancer MCF-7 cells.Oncology letters · 2021Article
- Impact of Community-Based Clinical Breast Examinations in Botswana.JCO global oncology · 2021Article
- Biological effect of ribosomal protein L32 on human breast cancer cell behavior.Molecular medicine reports · 2020Article
- Multicenter cross-sectional screening of theOncology letters · 2018Article
- Expression of Caspase-1 in breast cancer tissues and its effects on cell proliferation, apoptosis and invasion.Oncology letters · 2018Article
- Phosphoproteomic analysis of the antitumor effects of ginsenoside Rg3 in human breast cancer cells.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs one of its responses to the increasing global burden of breast cancer (BC), China has deployed a national registration and BC screening campaign. The present report describes these programs and the initial results of these national BC control strategies, highlighting the challenges to be considered. MATERIALS AND
methodsThe primary BC incidence and prevalence data were obtained from the Chinese National Central Cancer Registry. MapInfo software was used to map the geographic distribution and variation. The time trends were estimated by the annual percentage of change from 2003 to 2009. The description of the screening plans and preliminary results were provided by the Ministry of Health.
resultsChinese cancer registries were primarily developed and activated in the East and Coastal regions of China, with only 12.5% of the registries located in West China. Geographic variation was noted, with the incidence of BC higher in North China than in South China and in urban areas compared with rural areas. Of great interest, these registries reported that the overall BC incidence has been increasing in China, with an earlier age of onset compared with Western countries and a peak incidence rate at age 50. In response to this increasing incidence and early age of onset, BC screening programs assessed 1.46 million women aged 35-59 years, using clinical breast examinations and ultrasound as primary screening tools between 2009 and 2011. The diagnostic rate for this screening program was only 48.0/10(5) with 440 cases of early stage BC. Early stage BC was detected in nearly 70% of screened patients. Subsequently, a second-generation screening program was conducted that included older women aged 35-64 years and an additional 6 million women were screened.
conclusionThe cancer registration system in China has been uneven, with a greater focus on East rather than West China. The data from these registries demonstrate regional variation, an increasing BC incidence, and an early age of onset. The 2009 to 2011 BC screening program targeting women aged 35-59 years had a low detection rate that resulted in a second-generation screening program that extended the cohort size and ages screened to 35-64 years. IMPLICATIONS FOR PRACTICE: Cancer registration has been active in China for decades; however, a national survey of registries has not been routinely reported. This study used MapInfo to describe the reported data and found asymmetric registration activities, geographic variations in breast cancer (BC) burdens, and an increasing incidence with a peak at age 50. The initial Chinese BC screening programs focused on a relatively young population of women aged 35-59 years and had a low detection rate, but 69.7% of patients had early stage BC. Older women were included in the second-generation screening programs, and an additional 6 million women were screened. Consideration of regional variations and age is necessary to optimize the efficiency and utility of BC screening in China, with the ultimate goal to reduce BC mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.